Invention Grant
US08772301B2 Compounds for treating disorders mediated by metabotropic glutamate receptor 5, and methods of use thereof
有权
用于治疗由代谢型谷氨酸受体5介导的病症的化合物及其使用方法
- Patent Title: Compounds for treating disorders mediated by metabotropic glutamate receptor 5, and methods of use thereof
- Patent Title (中): 用于治疗由代谢型谷氨酸受体5介导的病症的化合物及其使用方法
-
Application No.: US12972293Application Date: 2010-12-17
-
Publication No.: US08772301B2Publication Date: 2014-07-08
- Inventor: Larry Wendell Hardy , Michele L. R. Heffernan , Frank Xinhe Wu , Kerry L. Spear , Lakshmi D. Saraswat
- Applicant: Larry Wendell Hardy , Michele L. R. Heffernan , Frank Xinhe Wu , Kerry L. Spear , Lakshmi D. Saraswat
- Applicant Address: US MA Marlborough
- Assignee: Sunovion Pharmaceuticals, Inc.
- Current Assignee: Sunovion Pharmaceuticals, Inc.
- Current Assignee Address: US MA Marlborough
- Agency: Choate, Hall & Stewart, LLP
- Agent Andrea L. Robidoux; Daniel A. Klein
- Main IPC: A61K31/519
- IPC: A61K31/519 ; A61K31/5365 ; A61K31/55 ; A61K31/551 ; A61K31/553 ; C07D471/04 ; C07D487/04 ; C07D498/04

Abstract:
Provided herein are compounds and methods of synthesis thereof. The compounds set forth herein are useful for the treatment, prevention, and/or management of various disorders, such as neurological disorders, neurodegenerative disorders, neuropsychiatric disorders, disorders of cognition, learning or memory, gastrointestinal disorders, lower urinary tract disorder, and cancer. Compounds set forth herein modulate the activity of metabotropic glutamate receptor 5 (mGluR5) in the central nervous system or the periphery. Pharmaceutical formulations containing the compounds and their methods of use are also provided herein.
Public/Granted literature
Information query
IPC分类: